GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Skye Bioscience Inc (NAS:SKYE) » Definitions » Shiller PE Ratio

SKYE (Skye Bioscience) Shiller PE Ratio : (As of Jan. 18, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Skye Bioscience Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Skye Bioscience Shiller PE Ratio Historical Data

The historical data trend for Skye Bioscience's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Skye Bioscience Shiller PE Ratio Chart

Skye Bioscience Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Skye Bioscience Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Skye Bioscience's Shiller PE Ratio

For the Biotechnology subindustry, Skye Bioscience's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Skye Bioscience's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Skye Bioscience's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Skye Bioscience's Shiller PE Ratio falls into.



Skye Bioscience Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Skye Bioscience's E10 for the quarter that ended in Sep. 2024 is calculated as:

For example, Skye Bioscience's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.1/133.0289*133.0289
=-0.100

Current CPI (Sep. 2024) = 133.0289.

Skye Bioscience Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201412 -37.500 99.070 -50.354
201503 -15.000 99.621 -20.030
201506 -32.500 100.684 -42.941
201509 -17.500 100.392 -23.189
201512 -10.000 99.792 -13.331
201603 -20.000 100.470 -26.481
201606 7.500 101.688 9.812
201609 -12.500 101.861 -16.325
201612 -17.500 101.863 -22.854
201703 -22.500 102.862 -29.099
201706 -5.000 103.349 -6.436
201709 -5.000 104.136 -6.387
201712 2.500 104.011 3.197
201803 -22.500 105.290 -28.428
201806 -5.000 106.317 -6.256
201809 -5.000 106.507 -6.245
201812 -12.500 105.998 -15.688
201903 -27.500 107.251 -34.110
201906 20.000 108.070 24.619
201909 -10.000 108.329 -12.280
201912 -5.000 108.420 -6.135
202003 -2.500 108.902 -3.054
202006 -2.500 108.767 -3.058
202009 -2.500 109.815 -3.028
202012 -2.500 109.897 -3.026
202103 -2.500 111.754 -2.976
202106 -2.500 114.631 -2.901
202109 -1.103 115.734 -1.268
202112 0.000 117.630 0.000
202203 -2.500 121.301 -2.742
202206 -2.500 125.017 -2.660
202209 -1.580 125.227 -1.678
202212 -3.940 125.222 -4.186
202303 -1.370 127.348 -1.431
202306 -0.800 128.729 -0.827
202309 -3.170 129.860 -3.247
202312 -0.358 129.419 -0.368
202403 -0.180 131.776 -0.182
202406 -0.200 132.554 -0.201
202409 -0.100 133.029 -0.100

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Skye Bioscience  (NAS:SKYE) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Skye Bioscience Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Skye Bioscience's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Skye Bioscience Business Description

Traded in Other Exchanges
N/A
Address
11250 El Camino Real, Suite 100, San Diego, CA, USA, 92130
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
Executives
Paul A. Grayson director 10578 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Kaitlyn Melanie Arsenault officer: Chief Financial Officer 11250 EL CAMINO REAL, SUITE 100, C/O SKYE BIOSCIENCE, INC., SAN DIEGO CA 92130
Punit Dhillon director 5820 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
5am Partners Vii, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Andrew J. Schwab director, 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
John D Diekman 10 percent owner C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Ventures Vii, L.p. 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kush Parmar 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Partners Ii, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Co-investors Ii Lp 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Versant Venture Capital Iii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Side Fund Iii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Ventures Iii, Llc 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Scott M Rocklage 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Ventures Ii Lp 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107